This reprogramming has far-reaching consequences, in which a distinct and unique gene set with acquired AR-responsive features provides prognostic potential for the survival of patients with prostate cancer, independent of classical prognostic parameters and clinical risk stratification system (D’Amico). This evidence concerns the gene AR and prostate cancer.